Pfizer Treatment for Psoriasis Shows Positive Results in Studies
22 April 2014 - 11:08PM
Dow Jones News
By Tess Stynes
Pfizer Inc. (PFE) said two Phase 3 studies to evaluate the
effectiveness and safety of its treatment for adults with
moderate-to-severe plaque psoriasis showed positive results.
The studies of the twice-daily pill--known as tofacitinib-- at
two dosing levels was more effective than a placebo in achieving a
response of "clear" or "almost clear" at 16 weeks and in the
portion of patients achieving at least a 75% reduction in the
severity and area affected by psoriasis.
Pfizer plans to submit a supplemental new drug application to
the U.S. Food and Drug Administration by early next year.
Tofacitinib--sold domestically under the brand name Xeljanz---is
approved in more than 20 countries for adults with hard-to-treat
cases of moderate-to-severe rheumatoid arthritis.
Write to Tess Stynes at tess.stynes@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2024 to May 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From May 2023 to May 2024